Adamson, SJ, Sellman, JD, Foulds, JA, et al. A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression. J Clin Psychopharmacol 2015; 35: 143–149Google Scholar

Adan-Manes, J, Novalbos, J, López-Rodríguez, R, et al. Lithium and venlafaxine interaction: a case of serotonin syndrome. J Clin Pharm Ther 2006; 31: 397–400Google Scholar

Adler, LA, Dirks, B, Deas, PF, et al. Lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2013; 74: 694–702Google Scholar

Afshar, M, Knapp, CM, Sarid-Segal, O, et al. The efficacy of mirtazapine in the treatment of cocaine dependence with comorbid depression. Am J Drug Alcohol Abuse 2012; 38: 181–186Google Scholar

Agabio, R, Trogu, E, Pani, PP. Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. Cochrane Database Syst Rev 2018; 4: CD008581Google Scholar

Agarwal, LJ, Berger, CE, Gill, L. Naltrexone for severe self-harm: a case report. Am J Psychiatry 2011; 168: 437–438Google Scholar

Agid, O, Siu, CO, Potkin, SG, et al. Meta-regression analysis of placebo response in antipsychotic trials, 1970–2010. Am J Psychiatry 2013; 170: 1335–1344Google Scholar

Aguglia, A, Mineo, L, Rodolico, A, et al. Asenapine in the management of impulsivity and aggressiveness in bipolar disorder and comorbid borderline personality disorder: an open-label uncontrolled study. Int Clin Psychopharmacol 2018; 33: 121–130Google Scholar

Ahmed, AO, Richardson, J, Buckner, A, et al. Do cognitive deficits predict negative emotionality and aggression in schizophrenia? Psychiatry Res 2018a; 259: 350–357Google Scholar

Ahmed, R, Kotapati, VP, Khan, AM, et al. Adding psychotherapy to the naltrexone treatment of alcohol use disorder: a meta-analytic review. Cureus 2018b; 10: e3107Google Scholar

Aiken, CB, Orr, C. Rechallenge with lamotrigine after a rash. Psychiatry (Edgmont) 2010; 7: 27–32Google Scholar

Airagnes, G, Lemogne, C, Renuy, A, et al. Prevalence of prescribed benzodiazepine long-term use in the French general population according to sociodemographic and clinical factors: findings from the CONSTANCS cohort. BMC Public Health 2019; 19: 566CrossRefGoogle ScholarPubMed

Albers, LJ, Ozdemir, V, Marder, SR. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose adjusted drug interaction strategy. J Clin Psychopharmacol 2005; 25: 170–174CrossRefGoogle ScholarPubMed

Albertini, E, Ernst, CL, Tamaroff, RS. Psychopharmacological decision making in bipolar disorder during pregnancy and lactation: a case-by-case approach to using current evidence. Focus 2019; 17: 249–258Google Scholar

Albott, CS, Lim, KO, Forbes, MK, et al. Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. J Clin Psychiatry 2018; 79: 17m11684CrossRefGoogle ScholarPubMed

Alexopoulos, GS, Canuso, CM, Gharabawi, GM, et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry 2008; 16: 21–30Google Scholar

Alexopoulos, GS, Katz, IR, Reynolds, CF 3rd, et al. The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. Postgrad Med 2001; Spec No Pharmacotherapy: 1–86Google Scholar

Allan, ER, Alpert, M, Sison, CE, et al. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. J Clin Psychiatry 1996; 57: 455–459Google Scholar

Allen, MH, Hirschfeld, RM, Wozniak, PJ, et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 2006; 163: 272–275Google Scholar

Allgulander, C, Mangano, R, Zhang, J, et al. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004; 19: 387–396Google Scholar

Alpert, M, Allan, ER, Citrome, L, et al. A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacol Bull 1990; 26: 367–371Google Scholar

Alphs, L, Davis, JM. Noncatecholaminergic treatments of tardive dyskinesia. J Clin Psychopharmachol 1982; 2: 380–385Google Scholar

Altemus, M, Neeb, CC, Davis, A, et al. Phenotypic differences between pregnancy-onset and postpartum-onset major depressive disorder. J Clin Psychiatry 2012; 73: e1485–e1491Google Scholar

Altshuler, LL, Bauer, M, Frye, MA, et al. Does thyroid supplementation accelerate tricyclic antidepressant response?: a review and meta-analysis of the literature. Am J Psychiatry 2001; 158: 1617–1622Google Scholar

Altshuler, LL, Post, RM, Hellemann, G, et al. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J Clin Psychiatry 2009; 70: 450–457Google Scholar

Altshuler, L, Suppes, T, Black, D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003; 160: 1252–1262Google Scholar

Altshuler, LL, Suppes, T, Black, DO, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry 2006; 163: 313–315Google Scholar

Alvarez, E, Perez, V, Dragheim, M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 2012; 15: 589–600Google Scholar

American Psychiatric Association. Practice Guideline for the Treatment of Major Depressive Disorder, 3rd Edn. Arlington, VA: American Psychiatric Association; 2010Google Scholar

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edn. Arlington, VA: American Psychiatric Association; 2013Google Scholar

American Society of Hospital Pharmacists. ASHP statement on pharmaceutical care. Am J Hosp Pharm. 1993; 50: 1720–1723Google Scholar

Amerio, A, Ossola, P, Scagnelli, F, et al. Safety and efficacy of lithium in children and adolescents: a systematic review in bipolar illness. Eur Psychiatry 2018; 54: 85–97Google Scholar

Amerio, A, Stubbs, B, Odone, A, et al. The prevalence and predictors of comorbid bipolar disorder and obsessive-compulsive disorder: a systematic review and meta-analysis. J Affect Disord 2015; 186: 99–109Google Scholar

Amieva, H, LeGoff, M, Millet, X, et al. Prodromal Alzheimer’s disease: successive emergence of the clinical symptoms. Ann Neurol 2008; 64: 492–498Google Scholar

Amital, D, Vishne, T, Roitman, S, et al. Open study of creatine monohydrate in treatment-resistant posttraumatic stress disorder. J Clin Psychiatry 2006; 67: 836–837CrossRefGoogle ScholarPubMed

Amsterdam, JD, Berwish, NJ. High dose tranylcypromine therapy for refractory depression. Pharmacopsychiatry 1989; 22: 21–25Google Scholar

Amsterdam, JD, Fawcett, J, Quitkin, FM, et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 1997; 154: 963–969Google Scholar

Amsterdam, JD, Li, Y, Soeller, I, et al. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J Clin Psychopharmacol 2009; 29: 378–382Google Scholar

Anand, A, Charney, DS, Oren, DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000; 57: 170–176Google Scholar

Anderson, M, Björkhem-Bergman, L, Beck, O. Possible mechanism for inhibition of morphine formation from 6-acetylmorphine after intake of street heroin. Forensic Sci Int 2015; 252: 150–156Google Scholar

Andrade, C. Nonsteroidal anti-inflammatory drugs and 5-HT3 serotonin receptor antagonists as innovative antipsychotic augmentation treatments for schizophrenia. J Clin Psychiatry 2014; 75: e707–e709Google Scholar

Andrade, C. Antidepressant exposure during pregnancy and risk of autism in the offspring: 1: meta-review of meta-analyses. J Clin Psychiatry 2017; 78: e1047–e1051Google Scholar

Andrade, C, Kisely, S, Monteiro, I, et al. Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials. J Psychiatry Res 2015; 60: 14–21CrossRefGoogle ScholarPubMed

Andrade, C, Sandarsh, S, Chetan, KB, et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010; 71: 1565–1575Google Scholar

Andreason, NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 1982; 39: 784–788Google Scholar

Andreason, NC, Liu, D, Ziebell, S, et al. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 2013; 170: 609–615CrossRefGoogle Scholar

Andreason, NC, Pressler, M, Nopoulos, P, et al. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010; 67: 255–262Google Scholar

Andrezina, R, Josiassen, RC, Marcus, RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison of intramuscular haloperidol. Psychopharmacology (Berl) 2006; 188: 281–292Google Scholar

Anglin, RES, Samaan, Z, Walter, SD, et al. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. Br J Psychiatry 2013; 202: 100–107Google Scholar

Anton, RF, Moak, DH, Latham, PK. The obsessive compulsive drinking scale: a new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry 1996; 53: 225–231. Erratum in: Arch Gen Psychiatry 1996; 53: 576Google Scholar

Anton, RF, Myrick, H, Wright, TM, et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry 2011; 168: 709–717Google Scholar

Anton, RF, O’Malley, SS, Ciraulo, DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study. A randomized controlled trial. J Am Med Assoc 2006; 295: 2003–2017Google Scholar

Anttila, S, Viikki, M, Huuhka, K, et al. TPH2 polymorphisms may modify clinical picture in treatment-resistant depression. Neurosci Lett 2009; 464: 43–46Google Scholar

Appelberg, BG, Syvälahti, EK, Koskinen, TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001; 62: 448–452Google Scholar

Appelhof, BC, Fliers, E, Wekking, EM, et al. Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial. J Clin Endocrinol Metab 2005; 90: 2666–2674Google Scholar

Arato, M, O’Connor, R, Meltzer, HY, et al. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002; 17: 207–215Google Scholar

Argolo, FC, Cavalcanti-Ribeiro, P, Netto, LR, et al. Prevention of posttraumatic stress disorder with propranolol: a meta-analytic review. J Psychosom Res 2015; 79: 89–93Google Scholar

Argyropoulou, P, Patakas, D, Koukou, A, et al. Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiration 1993; 60: 214–220Google Scholar

Arnold, LE. Methylphenidate vs. amphetamine: comparative review. J Attention Disord 2000; 4: 200–211Google Scholar

Arnold, LM, Mutasim, DF, Dwight, MM, et al. An open clinical trial of fluvoxamine treatment of psychogenic excoriation. J Clin Psychopharmacol 1999; 19: 15–18Google Scholar

Arnow, BA, Blasey, C, Williams, LM, et al. Depression subtypes in predicting antidepressant response: a report from the iSPOT-D trial. Am J Psychiatry 2015; 172: 743–750Google Scholar

Arns, M, Bruder, G, Hegerl, U, et al. EEG alpha asymmetry as a gender-specific predictor of outcome to acute treatment with different antidepressant medications in the randomized iSPOT-D study. Clin Neurophysiol 2016; 17: 509–519Google Scholar

Arntz, A, Van den Hoorn, M, Cornelis, J. Reliability and validity of the borderline personality disorder severity index. J Pers Disord 2003; 17: 45–59Google Scholar

Aronson, R, Offman, HJ, Joffe, RT, et al. Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 1996; 53: 842–848CrossRefGoogle ScholarPubMed

Askari, N, Moin, M, Sanati, M, et al. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2012; 26: 883–892Google Scholar

Astill Wright, L, Sijbrandij, M, Sinnerton, R, et al. Pharmacological prevention and early treatment of post-traumatic stress disorder and acute stress disorder: a systematic review and meta-analysis. Transl Psychiatry 2019; 9: 334Google Scholar

AstraZeneca. A multi-center, double-blind, randomized-withdrawal, parallel-group, placebo-controlled Phase III study of the efficacy and safety of quetiapine fumarate extended release (Seroquel XR^™) as monotherapy in the maintenance treatment of patients with major depressive disorder following an open-label stabilization period (AMETHYST study). www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/8579609 ClinicalTrials.gov ID NCT00278941. Study code: D1448C00005. 2008Google Scholar

Astrup, A, Caterson, I, Zelissen, P, et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004; 12: 1658–1669Google Scholar

Avgerinos, KI, Spyrou, N, Bougioukas, KI, et al. Effects of creatine supplementation on cognitive function of healthy individuals: a systematic review of randomized controlled trials. Exp Gerontol 2018; 108: 166–173Google Scholar

Awortwe, C, Makiwane, M, Reuter, H, et l. Critical evaluation of causality assessment of herb-drug interactions in patients. Br J Clin Pharmacol 2018; 84: 679–693Google Scholar

Azuma, K, Takaesu, Y, Soeda, H, et al. Ability of suvorexant to prevent delirium in patients in the intensive care unit: a randomized controlled trial. Acute Med Surg 2018; 5: 362–368Google Scholar

Baandrup, L, Ebdrup, BH, Rasmussen, JØ, et al. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev 2018; 3: CD011481Google Scholar

Babor, TF, Hofmann, M, DelBoca, FK, et al. Types of alcoholics, I: evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry 1992; 49: 599–608Google Scholar

Bacaltchuk, J, Hay, P, Mari, JJ. Antidepressants versus placebo for the treatment of bulimia nervosa: a systematic review. Aust N Z J Psychiatry 2000; 34: 310–317Google Scholar

Back, SE, McCauley, JL, Korte, KJ, et al. A double-blind, randomized, controlled pilot study of N-acetylcysteine in veterans with posttraumatic stress disorder and substance use disorders. J Clin Psychiatry 2016; 77: e1439–e1446Google Scholar

Bagby, RM, Ryder, AG, Cristi, C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J Psychiatry Neurosci 2002; 27: 250–257Google Scholar

Bahji, A, Forsyth, A, Groll, D, et al. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2020; 96: 109735Google Scholar

Baillon, SF, Narayana, U, Luxenberg, JS, et al. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev 2018; 10: CD003945Google Scholar

Bak, M, Weltens, I, Bervoets, C, et al. The pharmacological management of agitated and aggressive behaviour: a systematic review and meta-analysis. Eur Psychiatry 2019; 57: 78–100Google Scholar

Baker, RW, Kinon, BJ, Maguire, GA, et al. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 2003; 23: 342–348Google Scholar

BALANCE Investigators and Collaborators; Geddes, JR, Goodwin, GM, Rendell, J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375: 385–395Google Scholar

Baldaçara, L, Cogo-Moreira, H, Parreira, BL, et al. Efficacy of topiramate in the treatment of crack cocaine dependence: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2016; 77: 398–406Google Scholar

Baldessarini, RJ, Vázques, G, Tondo, L. Treatment of cyclothymic disorder: commentary. Psychother Psychosom 2011; 80: 131–135Google Scholar

Baldwin, DS, Loft, H, Dragheim, M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 2012; 22: 482–491Google Scholar

Bali, V, Chatterjee, S, Carnahan, RM, et al. Risk of dementia among elderly nursing home patients using paroxetine and other selective serotonin reuptake inhibitors. Psychiatr Serv 2015; 66: 1333–1340Google Scholar

Ballenger, JC, Davidson, JR, Lecrubier, Y, et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1998; 59(Suppl 8): 47–54Google Scholar

Bandelow, B. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol 1995; 2: 73–81Google Scholar

Baniasadi, M, Hosseini, G, Bordbar, MRF, et al. Effect of pregabalin augmentation in treatment of patients with combat-related chronic posttraumatic stress disorder: a randomized controlled trial. J Psychiatr Pract 2014; 20: 419–427Google Scholar

Banzi, R, Cusi, C, Randazzo, C, et al. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults. Cochrane Database Syst Rev 2015; 4: CD002919Google Scholar

Barbee, JG, Thompson, TR, Jamhour, NJ, et al. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry 2011; 72: 1405–1412Google Scholar

Bareggi, SR, Bianchi, L, Cavallaro, R, et al. Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results. CNS Drugs 2004; 18: 329–335Google Scholar

Barker, MJ, Greenwood, KM, Jackson, M, et al. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004; 18: 37–48CrossRefGoogle ScholarPubMed

Barnett, R, Maruff, P, Vance, A, et al. Abnormal executive function in attention deficit hyperactivity disorder: the effect of stimulant medication and age on spatial working memory. Psychol Med 2001; 31: 1107–1115Google Scholar

Barnett, SD, Kramer, ML, Casat, CD, et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 2002; 16: 365–368Google Scholar

Barrons, R, Roberts, N. The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome. J Clin Pharm Ther 2010; 35: 153–167Google Scholar

Barsky, AJ, Saintfort, R, Rogers, MP, et al. Nonspecific medication side effects and the nocebo phenomenon. J Am Med Assoc 2002; 287: 622–627Google Scholar

Batail, JM, Langrée, B, Robert, G, et al. Use of very-high dose olanzapine in treatment-resistant schizophrenia. Schizophr Res 2014; 159: 411–414Google Scholar

Batelaan, NM, Bosman, RC, Muntingh, A, et al. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. Br Med J 2017; 358: j3927Google Scholar

Bauer, M, Dell’Osso, L, Kasper, S, et al. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. J Affect Disord 2013; 151: 209–219Google Scholar

Bauer, MS, Whybrow, PC. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990; 47: 435–440Google Scholar

Baune, BT, Brignone, M, Larsen, KG. A network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. Int J Neuropsychopharmacol 2018; 21: 97–107Google Scholar

Bazire, SR. Sudden death associated with switching monoamine oxidase inhibitors. Drug Intell Clin Pharm 1986; 20: 954–956Google Scholar

Beasley, CM Jr, Tollefson, G, Tran, P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111–123Google Scholar

Beck, AT, Epstein, N, Brown, G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56: 893–897Google Scholar

Begemann, MJ, Dekker, CF, van Lunenburg, M, et al. Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophr Res 2012; 141: 179–184Google Scholar

Beinat, C, Banister, SD, Herrera, M, et al. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia. CNS Drugs 2015; 29: 529–542Google Scholar

Bellatuono, C, Tofani, S, Di Sciascio, G, et al. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen Hosp Psychiatry 2013; 35: 3–8Google Scholar

Bellino, S, Paradiso, E, Bogetto, F. Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry 2005; 66: 1111–1115Google Scholar

Bellino, S, Paradiso, E, Bogetto, F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry 2006; 67: 1042–1046Google Scholar

Bellino, S, Paradiso, E, Bogetto, F. Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder. Psychiatry Res 2008; 161: 206–212Google Scholar

Bellino, S, Bozzatello, P, Rinaldi, C, et al. Paliperidone ER in the treatment of borderline personality disorder: a pilot study of efficacy and tolerability. Depress Res Treat 2011; 2011: 680194Google Scholar

Bellino, S, Bozzatello, P, Rocca, G, et al. Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. J Psychopharmacol 2014; 28: 125–132Google Scholar

Bellino, S, Paradiso, E, Bozzatello, P, et al. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study. J Psychopharmacol 2010; 24: 333–339Google Scholar

Benazzi, F. Characteristics of bipolar II patients with interpersonal rejection sensitivity. Psychiatr Clin Neurosci 2001; 54: 499–501Google Scholar

Bergamaschi, MM, Queiroz, RH, Chagas, MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011; 36: 1219–1226CrossRefGoogle ScholarPubMed

Bergero-Miguel, T, García-Encinas, MA, Villena-Jimena, A, et al. Gender dysphoria and social anxiety: an exploratory study in Spain. J Sex Med 2016; 13: 1270–1278Google Scholar

Beri, A, Boydell, J. Clozapine in borderline personality disorder: a review of the evidence. Ann Clin Psychiatry 2014; 26: 139–144Google Scholar

Berk, M, Dean, OM, Cotton, SM, et al. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2014; 75: 628–636Google Scholar

Berlant, J. Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry 2004; 4: 24Google Scholar

Berlant, J, van Kammen, DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry 2002; 63: 15–20Google Scholar

Berlin, HA, Koran, LM, Jenike, MA, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2011; 72: 716–721Google Scholar

Berman, M, Marcus, RN, Swanink, R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 843–853Google Scholar

Berman, RM, Fava, M, Thase, ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14: 197–206Google Scholar

Bersudsky, Y. Phenytoin: an anti-bipolar anticonvulsant? Int J Neuropsychopharmacol 2006; 9: 479–484Google Scholar

Berwaerts, J, Lane, R, Nuamah, IF, et al. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord 2011; 129: 252–260Google Scholar

Berwaerts, J, Melkote, R, Nuamah, I, et al. A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. J Affect Disord 2012b; 138: 247–258Google Scholar

Berwaerts, J, Xu, H, Nuamah, I, et al. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study. J Affect Disord 2012a; 136: e51–e60Google Scholar

Beucke, JC, Sepulcre, J, Talukdar, T, et al. Abnormally high degree connectivity of the orbitofrontal cortex in obsessive-compulsive disorder. JAMA Psychiatry 2013; 70: 619–629Google Scholar

Bhatara, VS, Magnus, RD, Paul, KL, et al. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother 1998; 32: 432–436Google Scholar

Biederman, J, Faraone, SV, Keenan, K, et al. Evidence of familial association between attention deficit disorder and major affective disorders. Arch Gen Psychiatry 1991a; 48: 633–642Google Scholar

Biederman, J, Faraone, SV, Keenan, K, et al. Familial association between attention deficit disorder and anxiety disorders. Am J Psychiatry 1991b; 148: 251–256Google Scholar

Biederman, J, Fried, R, Tarko, L, et al. Memantine in the treatment of executive function deficits in adults with ADHD. J Atten Disord 2017; 21: 343–352Google Scholar

Biederman, J, Joshi, G, Mick, E, et al. A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder. CNS Neurosci Ther 2010; 16: 91–102Google Scholar

Biederman, J, Krishnan, S, Zhang, Y, et al. Efficacy and safety of lisdexamfetamine (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase 3, randomized, multicenter, double-blind, parallel-group study. Clin Ther 2007; 29: 450–463Google Scholar

Biederman, J, Lindsten, A, Sluth, LB, et al. Vortioxetine for attention deficit hyperactivity disorder in adults: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Psychopharmacol 2019; 33: 511–521Google Scholar

Biederman, J, Petty, CR, Wilens, TE, et al. Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry 2008a; 165: 107–115Google Scholar

Biederman, J, Seidman, LJ, Petty, CR, et al. Effects of stimulant medication on neuropsychological functioning in young adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008b; 69: 1150–1156Google Scholar

Biel, MG, Peselow, E, Mulcare, L, et al. Continuation versus discontinuation of lithium in recurrent bipolar illness: a naturalistic study. Bipolar Disord 2007; 9: 435–442Google Scholar

Bighelli, I, Castellazzi, M, Cipriani, A, et al. Antidepressants versus placebo for panic disorder in adults. Cochrane Database Syst Rev 2018; 4: CD010676Google Scholar

Bilder, RM, Goldman, RS, Volavka, J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159: 1018–1028Google Scholar

Binder, RL, Levy, R. Extrapyramidal reactions in Asians. Am J Psychiatry 1981; 138: 1243–1244Google Scholar

Birkeland, SF. Psychopharmacological treatment and course in paranoid personality disorder: a case series. Int Clin Psychopharmacol 2013; 28: 283–285Google Scholar

Birks, JS, Harvey, RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev 2018; (6): CD001190Google Scholar

Birmingham, CL, Goldner, EM, Bakan, R, et al. Controlled trial of zinc supplementation in anorexia nervosa. Int J Eat Disord 1994; 15: 231–235Google Scholar

Bisaga, A, Aharonovich, E, Garawi, F, et al. A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend 2006; 81: 267–274Google Scholar

Bishara, D, Olofinjana, O, Sparshatt, A, et al: Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J Clin Psychopharmacol 2013; 33: 329–335Google Scholar

Bishop, JR, Moline, J, Ellingrod, VL, et al. Serotonin 2A-1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 2006; 31: 2281–2288Google Scholar

Bisol, LW, Lara, DR. Low-dose quetiapine for patients with dysregulation of hyperthymic and cyclothymic temperaments. J Psychopharmacol 2001; 24: 421–424Google Scholar

Bivard, A, Lillicrap, T, Krishnamurthy, V, et al. MIDAS (Modafinil in Debilitating Fatigue After Stroke): a randomized, double-blind, placebo-controlled, cross-over trial. Stroke 2017; 48: 1293–1298Google Scholar

Bixby, AL, VandenBerg, A, Bostwick, JR. Clinical management of bleeding risk with antidepressants. Ann Pharmacother 2019; 53: 186–194Google Scholar

Black, DW, Gabel, J, Hansen, J, et al. A double-blind comparison of fluvoxamine versus placebo in the treatment of compulsive buying disorder. Ann Clin Psychiatry 2000; 12: 205–211Google Scholar

Black, N, Stockings, E, Campbell, G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry 2019; 6: 995–1010Google Scholar

Blackford, JU, Buckholtz, JW, Avery, SN, et al. A unique role for the human amygdala in novelty detection. Neuroimage 2010; 50: 1188–1193Google Scholar

Blanchard, EB, Jones-Alexander, J, Buckley, TC, et al. Psychometric properties of the PTSD checklist (PCL). Behav Res Ther 1996; 34: 699–673Google Scholar

Blessing, EM, Steenkamp, MM, Manzanares, J, et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 2015; 12: 825–836Google Scholar

Blier, P, Bergeron, R, de Montigny, C. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacology 1997; 16: 333–338Google Scholar

Blier, P, Ward, HE, Tremblay, P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010; 167: 281–288Google Scholar

Bloch, M, Schmidt, PJ, Danaceau, MA, et al. Dehydroandrosterone treatment of mid-life dysthymia. Biol Psychiatry 1999; 45: 1533–1541Google Scholar

Bloch, MH, Landeros-Weisenberger, A, Dombrowski, P, et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Biol Psychiatry 2007; 62: 839–846Google Scholar

Bloch, MR, Elliott, M, Thompson, H, et al. Fluoxetine in pathological skin-picking: open-label and double-blind results. Psychosomatics 2001; 42: 314–319Google Scholar

Blodgett, JC, Del Re, AC, Maisel, NC, et al. A meta-analysis of topiramate’s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res 2014; 38: 1481–1488Google Scholar

Blom, TJ, Mingione, CJ, Guerdjikova, AI, et al. Placebo response in binge eating disorder: a pooled analysis of 10 clinical trials from one research group. Eur Eat Disord Rev 2014; 22: 140–146Google Scholar

Bocchetta, A, Ardau, R, Fanni, T, et al. Renal function during long-term lithium treatment: a cross-sectional and longitudinal study. BMC Med 2015; 13: 12Google Scholar

Boeker, T. Ziprasidone and migraine headache. Am J Psychiatry 2002; 159: 1435–1436Google Scholar

Bogenschutz, MP, Nurnberg, GH. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65: 104–109Google Scholar

Boggs, DL, Kelly, DL, Feldman, S, et al. Quetiapine at high doses for the treatment of refractory schizophrenia. Schizophr Res 2008; 101: 347–348Google Scholar

Bohus, MJ, Landwehrmeyer, GB, Stiglmayr, CE, et al. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry 1999; 60: 598–603Google Scholar

Bonari, L, Pinto, N, Ahn, E, et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004; 49: 726–735Google Scholar

Bondolfi, G, Chautems, C, Rochat, B, et al. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology (Berl) 1996; 128: 421–425Google Scholar

Bondolfi, G, Lissner, C, Kosel, M, et al. Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. Int J Neuropsychopharmacol 2000; 3: 55–60Google Scholar

Bonn-Miller, MO, Loflin, MJE, Thomas, BF, et al. Labeling accuracy of cannabidiol extracts sold online. J Am Med Assoc 2017; 218: 1708–1709Google Scholar

Boonstra, E, de Kleijn, R, Colzato, LS, et al. Neurotransmitters as food supplements: the effects of GABA on brain and behavior. Front Psychol 2015; 6: 1520Google Scholar

Borison, RL, Arvanitis, LA, Miller, BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 1996; 16: 158–169Google Scholar

Borras, L, Huguelet, P, Eytan, A. Delusional “pseudotranssexualism” in schizophrenia. Psychiatry 2007; 70: 175–179Google Scholar

Bortnick, B, El-Khalili, N, Banov, M, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord 2011; 128: 83–94Google Scholar

Bose, A, Li, D, Gandhi, C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry 2008; 16: 14–20Google Scholar

Bottlender, R, Rudolf, D, Strauß, A, et al. Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disord 2001; 63: 79–83Google Scholar

Boulenger, J-P, Loft, H, Florea, I. A randomized clinical study of LuAA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 2012; 26: 1408–1416Google Scholar

Boulenger, J-P, Loft, H, Olsen, CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol 2014; 29: 138–149Google Scholar

Bourgeois, JA. The management of performance anxiety with beta adrenergic-blocking agents. Jefferson J Psychiatry 1991; 9: 13–28Google Scholar

Bourgeois, BF, D’Souza, J. Long-term safety and tolerability of oxcarbazepine in children: a review of clinical experience. Epilepsy Behav 2005; 7: 375–382Google Scholar

Bowden, CL, Calabrese, JR, Sachs, G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392–400Google Scholar

Bowden, CL, Janicak, PG, Orsulak, P, et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry 1996; 153: 765–770Google Scholar

Bowden, CL, Keck, PE Jr., McElroy, SL, et al. A randomized, placebo-controlled 12 month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57: 481–489Google Scholar

Bowden, CL, Singh, R, Weisler, P, et al. Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression. Acta Psychiatr Scand 2012; 126: 342–350Google Scholar

Bowden, CL, Vieta, E, Ice, KS, et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010; 71: 130–137Google Scholar

Bowtell, M, Eaton, S, Thien, K, et al. Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis. Schizophr Res 2018; 195: 231–236Google Scholar

Bozzatello, P, Rocca, P, Uscinska, M, et al. Efficacy and tolerability of asenapine compared with olanzapine in borderline personality disorder: an open-label randomized controlled trial. CNS Drugs 2017; 31: 809–819Google Scholar

Brady, K, Pearlstein, T, Asnis, G, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. J Am Med Assoc 2000; 283: 1837–1844Google Scholar

Braun, P, Greenberg, S, Dasberg, H, et al. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 1990; 51: 236–238Google Scholar

Brawman-Mintzer, O, Knapp, RG, Nietert, PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2005; 66: 1321–1325Google Scholar

Breier, A, Buchanan, RW, Kirkpatrick, B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151: 20–60Google Scholar

Breilmann, J, Girlanda, F, Guaiana, G, et al. Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database Syst Rev 2019; (3): CD010677Google Scholar

Breitbart, W, Rosenfeld, B, Kaim, M, et al. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 2001; 161: 411–420Google Scholar

Brekhman, II, Dardymov, IV. New substances of plant origin which increase nonspecific resistance. Ann Rev Pharmacol 1969; 9: 419–430Google Scholar

Bremner, JD, Shearer, K, McCaffery, P. Retinoic acid and affective disorders: the evidence for an association. J Clin Psychiatry 2012; 73: 37–50Google Scholar

Briggs-Gowan, MJ, Carter, S, Bosson-Heenan, J, et al. Are infant-toddler social-emotional and behavioral problems transient? J Am Acad Child Adolesc Psychiatry 2006; 45: 849–858Google Scholar

Britnell, SR, Jackson, AD, Brown, JN., et al. Aripiprazole for post-traumatic stress disorder: a systematic review. Clin Neuropharmacol 2017; 40: 273–278Google Scholar

Bro, SP, Kjaersgard, MI, Parner, ET, et al. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol 2015; 7: 139–147Google Scholar

Brown, WA. Placebo as a treatment for depression. Neuropsychopharmacology 1994; 10: 265–269Google Scholar

Brown, ES, Gabrielson, B. A randomized double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence. J Affect Disord 2012; 143: 257–260Google Scholar

Brown, ES, Gorman, AR, Hynan, LS. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol 2007; 27: 498–502Google Scholar

Brown, ES, Todd, JP, Hu, T, et al. A randomized, double-blind, placebo-controlled trial of citicoline for cocaine dependence in bipolar I disorder. Am J Psychiatry 2015; 172: 1014–1021Google Scholar

Bruder, GE, Sedoruk, JP, Stewart, JW, et al. Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre- and post-treatment findings. Biol Psychiatry 2008; 63: 1171–1177Google Scholar

Brunet, A, Saumier, D, Liu, A, et al. Reduction of PTSD symptoms with pre-reactivation propranolol therapy: randomized controlled trial. Am J Psychiatry 2018; 175: 427–433Google Scholar

Brunner, E, Tohen, M, Osuntokun, O, et al. Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. Neuropsychopharmacology 2014; 39: 2549–2559Google Scholar

Bruno, A, Micò, U, Pandolfo, G, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol 2012; 26: 1456–1462Google Scholar

Buchanan, RW, Breier, A, Kirkpatrick, B, et al. Positive and negative symptoms response to clozapine with and without the deficit syndrome. Am J Psychiatry 1998; 155: 751–760Google Scholar

Bugarski-Kirola, D, Iwata, N, Sameliak, S, et al. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. Lancet Psychiatry 2016; 3: 1115–1128Google Scholar

Buitelaar, JK, Sobanski, E, Stieglitz, RD, et al. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate. J Clin Psychiatry 2012; 73: 1097–1102Google Scholar

Burdick, KE, Endick, CJ, Goldberg, JF. Assessing cognitive deficits in bipolar disorder: are self-reports valid? Psychiatry Res 2005; 136: 43–50Google Scholar

Burdick, KE, Braga, RJ, Nnadi, CU, et al. Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J Clin Psychiatry 2012; 73: 103–112Google Scholar

Burdick, KE, Russo, M, Frangou, S, et al. Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. Psychol Med 2014; 44: 3083–3096Google Scholar

Bürkner, PC, Williams, DR, Simmons, TC, et al. Intranasal oxytocin may improve high-level social cognition in schizophrenia, but not social cognition or neurocognition in general: a multilevel Bayesian meta-analysis. Schizophr Bull 2017; 43: 1291–1303Google Scholar

Butterfield, MI, Becker, ME, Connor, KM, et al. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol 2001; 16: 197–203Google Scholar

Bystritsky, A, Kerwin, L, Feusner, JD, et al. A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder. Psychopharmacol Bull 2008; 41: 46–51Google Scholar

Cain, JW. Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a “therapeutic window”? J Clin Psychiatry 1992; 53: 272–277Google Scholar

Cakir, S, Kulakisizoglu, IB. The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: a 12-week open-label pilot study. Neuropsychiatr Dis Treat 2008; 4: 963–966Google Scholar

Calabrese, JR, Bowden, CL, Sachs, G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013–1024Google Scholar

Calabrese, JR, Bowden, CL, Sachs, GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79–88Google Scholar

Calabrese, JR, Keck, PE Jr, Starace, A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2015; 76: 284–292Google Scholar

Calabrese, JR, Pikalov, A, Streicher, C, et al. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol 2017a; 27: 865–876Google Scholar

Calabrese, JR, Sanchez, R, Jin, N, et al. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study. J Clin Psychiatry 2017b; 78: 324–331Google Scholar

Calabrese, JR, Shelton, MD, Rapport, DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005; 162: 2152–2161Google Scholar

Calabrese, JR, Suppes, T, Bowden, CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder: Lamictal 614 Study Group. J Clin Psychiatry 2000; 61: 841–850Google Scholar

Campbell, M, Adams, PB, Small, AM, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1995; 34: 445–453Google Scholar

Campbell, M, Small, AM, Green, WH, et al. Behavioral efficacy of haloperidol and lithium carbonate: a comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 1984; 41: 650–656Google Scholar

Canuso, CM, Singh, JB, Fedgchin, M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2018; 175: 620–630Google Scholar

Carbon, H, Hsieh, CH, Kane, JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry 2017; 78: e264–e278Google Scholar

Cardenas, D. Let not thy food be confused with thy medicine: the Hippocratic misquotation. E-SPEN 2013; 8: e260–e262Google Scholar

Careri, JM, Draine, AE, Hanover, R, et al. A 12-week double-blind, placebo-controlled, flexible-dose trial of vilazodone in generalized social anxiety disorder. Prim Care Companion CNS Disord 2015; 17: 10.4088/PCC.15m01831Google Scholar

Carey, P, Suliman, S, Ganesan, K, et al. Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Hum Psychopharmacol 2012; 27: 386–391Google Scholar

Carhart-Harris, RL, Bolstridge, M, Dy, CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl) 2018; 235: 399–408Google Scholar

Carman, J, Peuskens, S, Vangeneugden, A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 1995; 10: 207–213Google Scholar

Caroff, SN, Mann, SC. Neuroleptic malignant syndrome. Med Clin North Amer 1993; 77: 185–202Google Scholar

Carpenter, KM, Hasin, DS. Reliability and discriminant validity of the Type I/II and Type A/B alcoholic subtype classifications in untreated problem drinkers: a test of the Apollonian–Dionysian hypothesis. Drug Alcohol Depend 2001; 63: 51–67Google Scholar

Casamassima, F, Huang, J, Fava, M, et al. Phenotypic effects of bipolar liability gene among individuals with major depressive disorder. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 303–309Google Scholar

Casey, DE, Daniel, DG, Tamminga, C, et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology 2009; 34: 1330–1338Google Scholar

Casey, DE, Daniel, DG, Wassef, AA, et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003; 28: 182–192Google Scholar

Castells, X, Blanco-Silvente, L, Cunill, R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2018; 8: CD007813Google Scholar

Castells, X, Cunill, R, Pérez-Mañá, C, et al. Psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev 2016; 9: CD007380Google Scholar

Castro, VM, Roberson, AM, McCoy, TH, et al. Stratifying risk for renal insufficiency among lithium-treated patients: an electronic health record study. Neuropsychopharmacology 2016; 41: 1138–1143Google Scholar

Catalá-López, F, Hutton, B, Núñez-Beltrán, A, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS One 2017; 12: e0180355Google Scholar

Caye, A, Rocha, TB, Anselmi, L, et al. Attention-deficit/hyperactivity disorder trajectories from childhood to young adulthood: evidence from a birth cohort supporting a late-onset syndrome. JAMA Psychiatry 2016; 73: 705–712Google Scholar

Center for Behavioral Health Statistics and Quality (CBHSQ). Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. HHS Publication No. SMA 15–4927, NSDUH Series H-50. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015Google Scholar

Chakrabarti, A, Bagnall, A, Chue, P, et al. Loxapine for schizophrenia. Cochrane Database Syst Rev 2007; (4): CD001943Google Scholar

Chambers, CD, Hernandez-Diaz, S, Van Marter, LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New Engl J Med 2006; 354: 579–587Google Scholar

Chan, GC, Hinds, TR, Impey, S, et al. Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J Neurosci 1998; 18: 5322–5332Google Scholar

Chang, K, Saxena, K, Howe, M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006; 45: 298–304Google Scholar

Chang, HY, Tseng, PT, Stubbs, B, et al. The efficacy and tolerability of paliperidone in mania of bipolar disorder: a preliminary meta-analysis. Exp Clin Psychopharmacol 2017; 25: 422–433Google Scholar

Chang, SS, Liu, CM, Lin, SH, et al. Impaired flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives: the effect of genetic loading. Schizophr Bull 2009; 35: 213–221Google Scholar

Charney, DS. Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. Am J Psychiatry 2004; 161: 195–216Google Scholar

Charney, DA, Heath, LM, Zikos, E, et al. Poorer drinking outcomes with citalopram treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2015; 39: 1756–1765Google Scholar

Chaudhry, IB, Neelam, K, Duddu, V, et al. Ethnicity and Psychopharmacology. J Psychopharmachol 2008; 22: 673–680Google Scholar

Chekroud, AM, Gueorguieva, R, Krumholz, HM, et al. Reevaluating the efficacy and predictability of antidepressant treatments: a symptom clustering approach. JAMA Psychiatry 2017; 74: 370–378Google Scholar

Chen, JJ, Hua, H, Massihi, L, et al. Systematic literature review of quetiapine for the treatment of psychosis in patients with parkinsonism. J Psychiatry Clin Neurosci 2019a; 31: 188–195Google Scholar

Chen, JX, Su, YA, Bian, QT, et al. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology 2015; 58: 130–140Google Scholar

Chen, MH, Lin, WC, Wu, HJ, et al. Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD). J Affect Disord 2019b; 251: 162–169Google Scholar

Chen, TR, Huang, HC, Hsu, JH, et al. Pharmacological and psychological interventions for generalized anxiety disorder in adults: a network meta-analysis. J Psychiatr Res 2019c; 118: 73–83Google Scholar

Chen, YF, Wang, SJ, Khin, NA, et al. Trial design issues and treatment effect modeling in multi-regional schizophrenia trials. Pharm Stat 2010; 9: 217–229Google Scholar

Chengappa, KNR, Brar, JS, Gannon, JM, Schlicht, PJ. Adjunctive use of a standardized extract of Withania somnifera (ashwaganda) to treat symptom exacerbation in schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2018; 79: 17m11826Google Scholar

Chengappa, KN, Bowie, CR, Schlicht, PJ, et al. Randomized placebo-controlled adjunctive study of an extract of Withania somnifera for cognitive dysfunction in bipolar disorder. J Clin Psychiatry 2013; 74: 1076–1083Google Scholar

Chessick, CA, Allen, MH, Thase, M, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 2006; (3) :CD006115Google Scholar

Chiappini, S, Schifano, F. A decade of gabapentinoid misuse: an analysis of the European Medicines Agency’s “Suspected Adverse Drug Reactions” database. CNS Drugs 2016; 30: 647–654Google Scholar

Chick, J, Aschauer, H, Hornik, K, et al. Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug Alcohol Depend 2004; 74: 61–70Google Scholar

Cho, M, Lee, TY, Kwak, YB, et al. Adjunctive use of anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Aust N Z J Psychiatry 2019; 53: 742–759Google Scholar

Chollet, F, Tardy, J, Albucher, JF. Fluoxetine for motor recovery after stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011; 10: 123–130Google Scholar

Choy, Y, Peselow, ED, Case, BG, et al. Three-year medication prophylaxis in panic disorder: to continue or discontinue? A naturalistic study. Compr Psychiatry 2007; 48: 419–425Google Scholar

Christensen, J, Grønborg, TK, Sørensen, MJ. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. J Am Med Assoc 2013; 309: 1696–1703Google Scholar

Christenson, GA, MacKenzie, TB, Mitchell, JE, et al. A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. Am J Psychiatry 1991; 148: 1566–1571Google Scholar

Chung, YC, Lee, CR, Park, TW, et al. Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial. World J Biol Psychiatry 2009; 10: 156–162Google Scholar

Cipriani, A, Furukawa, TA, Salanti, G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391: 1357–1366Google Scholar

Citrome, L. The ABCs of dopamine receptor partial agonists – aripiprazole, brexpiprazole, and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract. 2015; 69: 1211–1220Google Scholar

Citrome, L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol 2017a; 37: 138–147Google Scholar

Citrome, L, Meng, X, Hochfeld, M. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr Research 2011; 131(1–3): 75–81Google Scholar

Citrome, L, Durgam, S, Lu, K, et al. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. J Clin Psychiatry 2016a; 77: 109–115Google Scholar

Citrome, L, Ota, A, Nagamizu, K, et al. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. Int Clin Psychopharmacol 2016b; 31: 192–201Google Scholar

Citrome, L, Landbloom, R, Chang, CT, et al. Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder. Neuropsychiatr Dis Res 2017b; 13: 2955–2963Google Scholar

Citrome, L, Volavka, J, Czobor, P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001; 52: 1510–1514Google Scholar

Ciudad, A, Alvarez, E, Roca, M, et al. Early response and remission as predictors of a good outcome of a major depressive episode at 12-month follow-up: a prospective, longitudinal, observational study. J Clin Psychiatry 2012; 73: 185–191Google Scholar

Claes, L, Bouman, WP, Witcomb, G, et al. Non-suicidal self-injury in trans people: associations with psychological symptoms, victimization, interpersonal functioning, and perceived social support. J Sex Med 2015; 12: 168–179Google Scholar

Clark, CT, Klein, AM, Perel, JM, et al. Lamotrigine dosing for pregnant patients with bipolar disorder. Am J Psychiatry 2013; 170: 1240–1247Google Scholar

Clark, RD, Canive, JM, Calais, LA, et al. Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress 1999; 12: 395–401Google Scholar

Clayton, AH, Stewart, RS, Fayyad, R, et al. Sex differences in clinical presentation and response in panic disorder: pooled data from sertraline treatment studies. Arch Womens Ment Health 2006; 9: 151–157Google Scholar

Clemons, WE, Makela, E, Young, J. Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report. Sleep Med 2004; 5: 509–511Google Scholar

Cloninger, CR. The Temperament and Character Inventory (TCI): A Guide to its Development and Use. St. Louis, MO: Washington University; Center for Psychobiology of Personality; 1994Google Scholar

Cloninger, CR, Przybeck, TR, Svrakic, DM. The Tridimensional Personality Questionnaire: US normative data. Psychol Rep 1991; 69: 1047–1057Google Scholar

Cloninger, CR, Zohar, AH, Hirschmann, S, et al. The psychological costs and benefits of being highly persistent: personality profiles distinguish mood disorders from anxiety disorders. J Affect Disord 2012; 136: 758–766Google Scholar

Clyde, PW, Harari, AE, Getka, EJ, et al. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. J Am Med Assoc 2003; 290: 2952–2958Google Scholar

Coccaro, EF, Kavoussi, RJ. Fluoxetine and impulsive aggressive behavior in personality disordered subjects. Arch Gen Psychiatry 1997; 54: 1081–1088Google Scholar

Coccaro, EF, Lee, RJ, Kavoussi, JR. A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. J Clin Psychiatry 2009; 70: 653–662Google Scholar

Coccaro, EF, Adan, F, Allen, D, et al. Plasma-serum differences in the assessment of tricyclic antidepressant blood levels. Int Clin Psychopharmacol 1987; 2: 217–224Google Scholar

Cohen, JM, Hernández-Díaz, S, Bateman, BT, et al. Placental complications associated with psychostimulant use in pregnancy. Obstet Gynecol 2017; 130: 1192–1201Google Scholar

Cohen, JM, Huybrechts, KF, Patorno, E, et al. Anticonvulsant mood stabilizer and lithium use and risk of adverse pregnancy outcomes. J Clin Psychiatry 2019; 80: 18m12572Google Scholar

Cohen, LG, Chesly, S, Eugenio, S, et al. Erythromycin-induced clozapine toxic reaction. Arch Intern Med 1996; 156: 675–677Google Scholar

Cohen, LS, Soares, CN, Poitras, JR, et al. Short-term use of estradiol for depression in perimenopausal and postmenopausal women: a preliminary report. Am J Psychiatry 2003; 160: 1519–1522Google Scholar

Cohen, LS, Viguera, AC, McInerney, KA, et al. Reproductive safety of second-generation antipsychotics: current data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Am J Psychiatry 2016; 173: 263–270Google Scholar

Cohen, NL, Ross, EC, Bagby, RM, et al. The 5-factor model of personality and antidepressant medication compliance. Can J Psychiatry 2004; 49: 106–113Google Scholar

Cole, JD, Kazarian, SS. The Level of Expressed Emotion Scale: a new measure of expressed emotion. J Clin Psychol 1988; 44: 392–397Google Scholar

Comer, JS, Olfson, M, Mojtabai, R. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996–2007. J Am Acad Child Adolesc Psychiatry 2010; 49: 1001–1010Google Scholar

Compton, WM, Han, B, Blanco, C, et al. Prevalence and correlates of prescription stimulant use, misuse, use disorders, and motivations for misuse among adults in the United States. Am J Psychiatry 2018; 175: 741–755Google Scholar

Conley, RR, Kelly, DL, Richardson, CM, et al. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol 2003; 23: 668–671Google Scholar

Connor, DF, Fletcher, KE, Swanson, JM, et al. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38: 1551–1559Google Scholar

Connor, KM, Davidson, JRT, Churchill, LE, et al. Psychometric properties of the Social Phobia Inventory. Br J Psychiatry 2000; 176: 379–386Google Scholar

Connor, KM, Davidson, JR, Weisler, RH, et al. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology 2006; 184: 21–25Google Scholar

Connor, KM, Hidalgo, RB, Crockett, B, et al. Predictors of treatment response in patients with posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 337–345Google Scholar

Conus, P, Cotton, SM, Francey, SM, et al. Predictors of favourable outcome in young people with a first episode psychosis without antipsychotic medication. Schizophr Res 2017; 185: 130–136Google Scholar

Cook, IA, Hunter, AM, Gilmer, WS, et al. Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD) trial. J Clin Psychiatry 2013; 74: 51–56Google Scholar

Cools, R, Robbins, TW. Chemistry of the adaptive mind. Philos Trans A Math Phys Eng Sci 2004; 362: 2871–2888Google Scholar

Cooper, TB, Bergner, PE, Simpson, GM. The 24-hour serum lithium level as a prognosticator of dosage requirements. Am J Psychiatry 1973; 130: 601–603Google Scholar

Cooper-Karaz, R, Apter, JT, Cohen, R, et al. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2007; 64: 679–688Google Scholar

Corá-Locatelli, G, Greenberg, BD, Martin, J, et al. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder. J Clin Psychiatry 1998; 59: 480–481Google Scholar

Cordás, TA, Tavares, H, Calderoni, DM, et al. Oxcarbazepine for self-mutilating bulimic patients. Int J Neuropsychopharmacol 2006; 9: 769–771Google Scholar

Cornelius, JR, Salloum, IM, Ehler, JG, et al. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54: 700–705Google Scholar

Cornelius, JR, Salloum, IM, Thase, ME, et al. Fluoxetine versus placebo in depressed alcoholic cocaine abusers. Psychopharmacol Bull 1998; 34: 117–121Google Scholar

Cornelius, JR, Soloff, PH, George, A, et al. Haloperidol vs. phenelzine in continuation therapy of borderline disorder. Psychopharmacol Bull 1993; 29: 333–337Google Scholar

Correll, CU, Kane, JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol 2007; 17: 647–656Google Scholar

Correll, CU, Davis, RE, Weingart, M, et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized trial. JAMA Psychiatry 2020; 77: 349–358Google Scholar

Correll, CU, Leucht, S, Kane, JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414–425Google Scholar

Correll, CU, Rubio, JM, Kane, JM. What is the risk-benefit ratio of long-term antipsychotic treatment in patients with schizophrenia? World Psychiatry 2018; 17: 149–160Google Scholar

Correll, CU, Manu, P, Olshanskiy, V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. J Am Med Assoc 2009; 302: 1765–1773Google Scholar

Correll, CU, Rubio, JM, Inczedy-Farkas, G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 2017; 74: 675–684Google Scholar

Correll, CU, Skuban, A, Hobart, M, et al. Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies. Schizophr Res 2016; 174: 82–92Google Scholar

Cortese, S, Adamo, N, Del Giovane, C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018; 5: 727–738Google Scholar

Corya, SA, Williamson, D, Sanger, TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006; 23: 364–372Google Scholar

Coryell, W, Winokur, G, Solomon, D, et al. Lithium and recurrence in a long-term follow-up of bipolar affective disorder. Psychol Med 1997; 27: 281–289Google Scholar

Costi, S, Soleimani, L, Glasgow, A, et al. Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial. Neuropsychopharmacol 2019; 44: 1812–1819Google Scholar

Coupland, CAC, Hill, T, Dening, T, et al. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med 2019; 179: 1084–1093Google Scholar

Cowdry, RW, Gardner, DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988; 45: 111–119Google Scholar

Crawford, MJ, Sanatinia, R, Barrett, B, et al. The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. Am J Psychiatry 2018; 175: 756–764Google Scholar

Crippa, JA, Derenusson, GN, Ferrari, TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011; 25: 121–130Google Scholar

Cristancho, P, Lenze, EJ, Dixon, D, et al. Executive function predicts antidepressant treatment noncompletion in late-life depression. J Clin Psychiatry 2018; 79: 16m11371Google Scholar

Cross-Disorder Group of the Psychiatric Genomics Consortium. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 2013; 45: 984–994Google Scholar

Crossley, NA, Constante, M. Efficacy of atypical v typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 2010; 196: 434–439Google Scholar

Crossley, NA, Marques, TR, Taylor, H, et al. Connectomic correlates of response to treatment in first-episode psychosis. Brain 2017; 140: 487–496Google Scholar

Cummings, JL, Lyketsos, CG, Peskind, ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. J Am Med Assoc 2015; 314: 1242–1254Google Scholar

Cutler, AJ, Montgomery, SA, Feifel, D, et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 2009; 70: 526–539Google Scholar

Czerwensky, F, Leucht, S, Steimer, W. MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain? Int J Neuropsychopharmacol 2013; 16: 2103–2109Google Scholar

Czobor, P, Volavka, J, Meibach, RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995; 15: 243–249Google Scholar

D’Abreu, A, Friedman, JH. Tardive dyskinesia-like syndrome due to drugs that do not block dopamine receptors: rare or non-existent. Literature review. Tremor Other Hyperkinet Mov (NY) 2018; 8: 570Google Scholar

Dackis, CA, Kampman, KM, Lynch, KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacol 2005; 30: 205–211Google Scholar

Dackis, CA, Kampman, KM, Lynch, KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J Subst Abuse Treat 2012; 43: 303–312Google Scholar

Dager, SR, Khan, A, Cowley, DS, et al. Characteristics of placebo response during long-term treatment of panic disorder. Psychopharmacol Bull 1990; 26: 273–278.Google Scholar

Daly, C, Griffin, E, Ashcroft, DM, et al. Intentional drug overdose involving pregabalin and gabapentin: findings from the National Self-Harm Registry Ireland, 2007–2015. Clin Drug Investig 2018a; 38: 373–380Google Scholar

Daly, J, Singh, JB, Fedgchin, M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 2018b; 75: 139–148Google Scholar

Daly, J, Trivedi, MH, Janik, A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention of patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 2019; 76: 893–903Google Scholar

Daniel, DG, Zimbroff, DL, Potkin, SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999; 20: 491–505Google Scholar

Dannlowski, U, Baune, BT, Böckemann, I, et al. Adjunctive antidepressant treatment with quetiapine in agitated depression: positive effects on symptom reduction, psychopathology and remission rates. Hum Psychopharmacol 2008; 23: 587–593Google Scholar

Daray, FM, Thommi, SB, Ghaemi, SN. The pharmacogenetics of antidepressant-induced mania: a systemic review and meta-analysis. Bipolar Disord 2010; 12: 702–706Google Scholar

Darbinyan, V, Aslanyan, G, Amroyan, E, et al. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry 2007; 61: 343–348Google Scholar

Davanzano, R, Dal Bo, S, Bua, J, et al. Antiepileptic drug and breastfeeding. Ital J Pediatr 2013; 39: 50Google Scholar

Davidson, J, Baldwin, D, Stein, DJ, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry 2006; 63: 1158–1165Google Scholar

Davidson, J, Pearlstein, T, Londborg, P, et al. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 2001a; 158: 1974–1981Google Scholar

Davidson, J, Stein, DJ, Rothbaum, BO, et al. Resilience as a predictor of treatment response in patients with posttraumatic stress disorder treated with venlafaxine extended release or placebo. J Psychopharmacol 2012; 26: 778–783Google Scholar

Davidson, JR, Book, SW, Colket, JT, et al. Assessment of a new self-rating scale for post-traumatic stress disorder. Psychol Med 1997a; 27: 153–160Google Scholar

Davidson, JR, Malik, ML, Sutherland, SN. Response characteristics to antidepressants and placebo in post-traumatic stress disorder. Int Clin Psychopharmacol 1997b; 12: 291–296Google Scholar

Davidson, JR, Potts, N, Richichi, E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993; 13: 423–428Google Scholar

Davidson, JR, Potts, NL, Richichi, EA, et al. The Brief Social Phobia Scale. J Clin Psychiatry 1991; (52 Suppl): 48S–51SGoogle Scholar

Davidson, JR, Rothbaum, BO, van der Kolk, BA et al. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001b; 58: 485–492Google Scholar

Davidson, M, Emsley, R, Kramer, M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007; 93: 117–130Google Scholar

Davis, JM. Dose equivalence of the antipsychotic drugs. J Psychiatr Res 1974; 11: 65–69Google Scholar

Davis, LL, Barotlucci, A, Petty, F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005; 85: 259–266Google Scholar

Davis, LL, Davidson, JR, Ward, LC, et al. Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol 2008a; 28: 84–88Google Scholar

Davis, LL, Ota, A, Perry, P, et al. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study. Brain Behav 2016; 6: e00520Google Scholar

Davis, LL, Ward, C, Rasmussen, C, et al. A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. Psychopharmacol Bull 2008b; 41: 8–18Google Scholar

Davison, JM, Dunlop, W. Renal hemodynamics and tubular function in normal human pregnancy. Kidney Int 1980; 18: 152–161Google Scholar

de Bejczy, A, Söderpalm, B. The effects of mirtazapine versus placebo on alcohol consumption in male high consumers of alcohol: a randomized, controlled trial. J Clin Psychopharmacol 2015; 35: 43–50Google Scholar

Debonnel, G, Saint-André, E, Hébert, C, et al. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol 2007; 10: 51–61Google Scholar

De Hert, M, Sermon, J, Geerts, P, et al. The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics. CNS Drugs 2015; 29: 637–658Google Scholar

DeKosky, ST, Williamson, JD, Fitzpatrick, AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. J Am Med Assoc 2008; 300: 2253–2262Google Scholar

de la Fuente, JM, Lotstra, F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 1994; 4: 479–486Google Scholar

de Leon, J, Wynn, G, Sandson, NB. The pharmacokinetics of risperidone versus paliperidone. Psychosomatics 2010; 51: 80–88Google Scholar

de Lucena, D, Fernandes, BS, Berk, M, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 2009; 70: 1416–1423Google Scholar

DeMartinis, A, Schweizer, E, Rickels, K. An open-label trial of nefazodone in high comorbidity panic disorder. J Clin Psychiatry 1996; 57: 245–248Google Scholar

Deng, L, Sun, X, Qiu, S, et al. Interventions for management of post-stroke depression: a Bayesian network meta-analysis of 23 randomized controlled trials. Sci Rep 2017; 7: 16466Google Scholar

Dennis, CL, Ross, LE, Herxheimer, A. Oestrogens and progestins for preventing and treating postpartum depression. Cochrane Database Syst Rev 2008;(4):CD001690Google Scholar

de Oliveira, IR, de Sena, EP, Pereira, EL, et al. Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis. J Clin Pharm Ther 1996; 21: 229–236Google Scholar

DePetris, AE, Cook, BL. Differences in diffusion of FDA antidepressant risk warnings across racial-ethnic groups. Psychiatr Serv 2013; 64: 466–471Google Scholar

De Picker, L, Van Den Eede, F, Dumont, G, et al. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. Psychosomatics 2014; 55: 536–537Google Scholar

Depping, AM, Komossa, K, Kissling, W, Leucht, S. Second generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev 2010; (12): CD008120Google Scholar

de Silva, VA, Suraweera, C, Ratnatuga, SS, et al. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry 2016; 16: 341Google Scholar

de Vries, C, van Bergen, A, Regeer, EJ, et al. The effectiveness of restarted lithium treatment after discontinuation: reviewing the evidence for discontinuation-induced refractoriness. Bipolar Disord 2013; 15: 645–649Google Scholar

Devulapalli, KK, Nasrallah, HA. An analysis of the high psychotropic off-label use in psychiatric disorders. The majority of psychiatric diagnoses have no approved drug. Asian J Psychiatry 2009; 2: 29–36Google Scholar

DeYoung, CG, Hirsh, JB, Shane, MS, et al. Testing predictions from personality neuroscience: brain structure and the big five. Psychol Sci 2010; 21: 820–828Google Scholar